Search

Selection Criteria for Insulin Pumps & AID

GettyImages-1397165147_700x400
Important pump differences can impact individual suitability.

Content Developed By: Katherine Krieder Evans and Dana Roseman

Tool Created and Reviewed by: ADCES Tech Committee and the danatech staff

After reviewing this content, healthcare professionals should be able to:

  1. Identify key factors influencing insulin pump and infusion set selection.

  2. Evaluate compatibility, usability, and coverage considerations for individual patients.

  3. Guide patients in selecting and maintaining appropriate diabetes technology for optimal outcomes.

Assisting With Pump & Infusion Set Selection

Selecting an insulin pump and infusion set that align with an individual’s lifestyle, preferences, and clinical profile is critical for successful diabetes management. While all pumps and infusion sets share fundamental design features, small differences can significantly impact comfort, usability, and treatment satisfaction.

Why the Right Fit Matters

Although most insulin pumps can be returned within 30 days, very few people with diabetes (PWD) do so. After that window closes, users are often locked into their choice until the device’s warranty expires. Fortunately, as automated insulin delivery (AID) systems are increasingly covered under pharmacy benefits, switching or upgrading has become more accessible.

Individuals who aren’t familiar with their device options may end up with a pump or infusion set that isn’t well suited to their needs. It’s the responsibility of diabetes care and education specialists (DCESs) and other healthcare professionals to stay informed about the latest pump and infusion technologies, integrated sensors, and insertion devices to guide patient-centered selection.

Quick Insight: A well-matched device improves adherence, confidence, and quality of life.

Step 1: Confirm Coverage

Start the process by verifying the person’s insurance coverage or self-pay options.

  • Private insurance: Most allow members to choose from several insulin pump options.

  • Government or select private plans: Some may only cover specific brands or models.

Tip: Direct patients to danatech’s Insulin Pump Comparison Pages for detailed, unbiased device comparisons. Encourage them to contact manufacturers for “test drives” or demo experiences before committing.

Step 2: Evaluate Pump Features

When reviewing available pumps, consider both clinical functionality and user experience.

FeatureClinical & Practical Considerations
Insulin VolumeDoes the reservoir hold enough for 2–3 days of use? Are basal increments small enough for fine adjustments?
Display ReadabilityCan the user easily see screen text and symbols, even in sunlight or low light?
Alarms & AlertsAre tones and vibrations adjustable? Can the user reliably detect them?
Water ResistanceIs a waterproof device necessary for swimming or humid environments?
Data ManagementIs data easy to download and share with the care team? Does it support cloud-based review?
CGM IntegrationDoes the pump pair with a CGM to automate insulin adjustments?
Sensor-Driven AdjustmentsCan the device modify basal rates, deliver correction doses, or suspend insulin for predicted lows?
Meter ConnectivityDoes it communicate directly with compatible blood glucose meters?
Remote CapabilitiesAre remote bolusing or caregiver control features desired?
Infusion Set CompatibilityWhich sets are compatible, and do they meet the person’s needs?
Ease of UseIs programming intuitive? How many steps are required for common actions?
Form FactorIs the pump’s size, weight, and color acceptable? Are wearing accessories available?
Custom AlertsAre site-change, missed bolus, or reminder features helpful?
Tubed vs. Patch PumpWill tubing interfere with activities or comfort?
Manufacturer SupportWhat is the company’s customer service reputation? How responsive is warranty replacement?

Step 3: Choose the Right Infusion Set

Infusion sets are as individualized as pumps themselves. For tubed pumps, selecting the right set is critical to ensure reliable insulin delivery, comfort, and minimal site complications. However, patch-style pumps (such as the Omnipod® system) deliver insulin through an integrated cannula and do not require a separate infusion set or tubing, simplifying the setup and reducing the number of supplies.

Assess for the following:

  • Cannula Type: Teflon® (soft) vs. stainless steel (metal)

  • Length: Choose based on body composition and site depth

  • Tubing Length: Shorter for low-profile wear, longer for flexibility

  • Insertion Angle: Straight (90°) or angled (20–45°) depending on tissue and comfort

  • Adhesion Strength: Should accommodate sweat, activity, or moisture exposure

  • Insertion Method: Manual vs. automatic device based on dexterity

  • Aesthetics: Visibility, comfort, and user preference for wear location

If an infusion set isn’t specified during ordering, a “default” set may be shipped—often not the best fit. Taking time to match the set to individual needs helps prevent frustration and therapy discontinuation.

Practice Pearl: Encourage patients to rotate sites consistently and inspect for lipohypertrophy or irritation.
Key Takeaways

  • Device selection should balance clinical performance with personal preference.
  • Encourage hands-on trials when possible.
  • Stay informed about insurance coverage and emerging technologies.
  • Reinforce site care and infusion set rotation as part of ongoing education.

Explore More on danatech

Learning Question:

Which of the following factors most directly influences whether a pump user can switch to a different device after purchase?

A) Display size

B) Insurance coverage and warranty terms

C) Reservoir volume

D) Type of infusion set

(Answer: B — coverage and warranty determine replacement flexibility.)

 

References

Grouped by the claim each source supports. Primary and official sources — ADA, FDA, danatech, peer-reviewed — are tagged and listed first within each group. Compiled and verified July 2026.

2026 ADA Standards of Care & AID as preferred delivery
  1. 1. American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2026. Diabetes Care. 2026;49(Suppl 1):S150–S178. AID is the standard of care and preferred delivery method for people with type 1 diabetes who can safely use the device; rec. 7.27 supports open-source AID management advice.Primary
    Diabetes Care 2026 (Section 7)
  2. 2. American Diabetes Association. ADA Releases "Standards of Care in Diabetes—2026." Press release, Dec 2025. Confirms new guidance removing prior treatment prerequisites before initiating CSII or AID.Primary
    ADA press release
  3. 3. CGM: ADA 2026 Standards of Care. American Academy of Family Physicians. Documents Rec. 7.8a — no requirement for C-peptide, islet autoantibodies or insulin-treatment duration before CSII or AID.
    AAFP summary
What integration is — and why not every integrated pump is AID
  1. 4. Boughton CK, Hovorka R. Automated insulin delivery in adults. Review describing sensor-augmented pump therapy and low-glucose suspend / predictive low-glucose management as distinct from full AID.
    PMC6986367
  2. 5. Sensor-Augmented Insulin Pumps and Hypoglycemia Prevention in Type 1 Diabetes. Describes SAP with and without automated insulin suspension — the integration-without-full-AID category the page distinguishes.
    PMC5375081
  3. 6. Closed-Loop Insulin Delivery Versus Sensor-Augmented Pump Therapy in Older Adults With Type 1 Diabetes (ORACL). Diabetes Care. 2022;45(2):381. Contrasts closed-loop AID against SAP in "manual mode" with optional low-glucose suspend.
    Diabetes Care 2022
Meal input differs by system (including the iLet)
  1. 7. U.S. Food and Drug Administration. FDA Clears New Insulin Pump and Algorithm-Based Software (iLet). Confirms the iLet replaces conventional carb counting with a meal-announcement feature and initializes on body weight alone.Primary
    FDA press announcement
  2. 8. danatech / ADCES. FDA Approves iLet Bionic Pancreas. danatech's own coverage of the meal-announcement mechanism.danatech
    danatech news
  3. 9. Beta Bionics. Meal Announcements Guide for iLet Bionic Pancreas. Manufacturer instruction: announce the meal when eating begins, not before; do not announce if more than 30 minutes have passed; do not use to correct highs.Manufacturer
    Beta Bionics guide
Correction behavior, bolus workflow & insulin stacking
  1. 10. American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2026. (See ref. 1.) Supports individualized device selection and system-specific use rather than a single correction rule.Primary
  2. 11. Beta Bionics. Meal Announcements Guide for iLet Bionic Pancreas. (See ref. 9.) Instruction not to use meal announcements to correct a high, illustrating why correction workflow is system-specific.Manufacturer
CGM data gaps, questionable readings & confirming with a meter
  1. 12. diaTribe. Your Guide to the 2026 ADA Standards of Care. Summarizes the Standards' guidance to use a glucometer when CGM readings don't match symptoms, e.g. during warm-up periods.
    diaTribe guide
  2. 13. American Diabetes Association. 7. Diabetes Technology: Standards of Care in Diabetes—2026. (See ref. 1.) Underlying recommendation for confirmatory glucose-meter use.Primary
Insulin-delivery failure: AID cannot confirm insulin is reaching the body
  1. 14. danatech / ADCES. Troubleshooting Unexplained Hyperglycemia. danatech's own step-by-step guidance: mechanical, behavioral and metabolic causes of unexplained highs; when to check ketones; when to seek emergency care for DKA.danatech
    danatech troubleshooting
  2. 15. Howsmon DP, et al. Early Detection of Infusion Set Failure During Insulin Pump Therapy in Type 1 Diabetes. Confirms infusion-set failure can cause prolonged hyperglycemia or DKA, characterized by rising glucose despite increased insulin infusion.
    PMC5094340
  3. 16. Frequent Insulin Infusion Site Failures "a Huge Problem." Medscape, Mar 2026. Reports that a large share of AID users experience infusion-site failures; unexplained hyperglycemia can serve as a clinical proxy for undetected occlusion.
    Medscape report

Primary = official ADA, FDA, danatech or peer-reviewed source. Manufacturer = manufacturer product or labeling page.

All URLs verified accessible July 2026. Device insulin clearances and indications should be confirmed against the current IFU. The page defers current-device specifics to Find & Compare, so no device-model citations are listed here.

The Danatech Digest

Join 25,000+ professionals who get our latest diabetes technology updates

DISCLAIMERS: 

This site and its services do not constitute the practice of medical advice, diagnosis or treatment. Always talk to your diabetes care and education specialist or health care provider for diagnosis and treatment, including your specific medical needs. If you have or suspect that you have a medical problem or condition, please contact a qualified health care professional immediately. To find a diabetes care and education specialist near you, visit the ADCES finder tool.

ADCES and danatech curate product specifics and periodically review them for accuracy and relevance. As a result, the information may or may not be the most recent. We recommend visiting the manufacturer's website for the latest details if you have any questions.

danatech is Made Possible by Grant Funding and Industry Sponsorship